Clearmind Medicine announced that it has filed an Israeli patent application for a combination therapy of 5‑methoxy‑2‑aminoindane (MEAI) and N‑acylethanolamines such as palmitoylethanolamide (PEA) to treat major depressive disorder. The filing is the result of a collaboration with Neurothera Labs, a subsidiary of SciSparc Ltd., and builds on Clearmind’s existing MEAI platform that has already been applied to alcohol use disorder and binge‑behavior indications.
By securing protection in Israel, Clearmind extends its global intellectual‑property coverage into a new therapeutic area, positioning the company to pursue clinical trials and potential regulatory submissions for depression treatment. The move also broadens the company’s pipeline beyond its current focus on addiction and behavioral disorders, underscoring a strategy to leverage MEAI’s non‑hallucinogenic profile across multiple indications.
The patent filing comes at a time when Clearmind is facing financial headwinds. The company recently received a Nasdaq notification for a minimum stockholders’ equity deficiency, falling short of the required $2.5 million, and has launched a small equity raise to fund ongoing operations and development. These developments have contributed to a sharp decline in investor sentiment, with the stock price falling nearly 58% over the week preceding the filing announcement.
Market reaction to the filing has been muted, reflecting broader concerns about the company’s financial footing rather than the patent itself. Analysts and investors have focused on the Nasdaq deficiency and the need for additional capital, which have outweighed the positive implications of the new intellectual‑property asset.
CEO Adi Zuloff‑Shani said, “This patent application marks another important milestone in our mission to develop novel, science‑backed solutions for some of the world’s most challenging mental health conditions. Depression affects hundreds of millions of people globally, yet treatment innovation has lagged for decades. We believe that our work with Neurothera continues to generate promising therapeutic pathways, and this new filing further strengthens our IP position as we advance MEAI‑based treatments toward clinical development.”
The filing strengthens Clearmind’s IP strategy and provides a foundation for future clinical development in depression, but the company’s current financial challenges underscore the need for continued capital support and disciplined execution to translate the patent into a viable product.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.